NIKKEI 225
27,011.33 -120.01 (-0.44%) HANG SENG
24,265.99 +22.38 (+0.09%) CRUDE OIL
85.51 -0.09 (-0.11%) GOLD FUTURES
1,847.00 -5.50 (-0.30%) DOW
34,297.73 -66.77 (-0.19%) BTC-GBP
27,659.11 +896.18 (+3.35%)
COMPASS Pathways plc (CMPS)
After hours:
| Previous close | 15.77 |
| Open | 15.06 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's range | 14.81 - 16.16 |
| 52-week range | 14.04 - 58.62 |
| Volume | |
| Avg. volume | 811,340 |
| Market cap | 654.345M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.68 |
| Earnings date | 09 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 82.10 |
- Globe Newswire
Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, and Sermo, a global leader in physician insights, today announced findings from a survey of Sermo physician members that showed two thirds (66%) of doctors surveyed believe psilocybin therapy has potential therapeutic benefit for patients with treatment-resistant depression (TRD). More than 320 milli
- Globe Newswire
COMPASS Pathways to participate in H.C. Wainwright investor conference
LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference, available on demand from 10 to 13 January. An audio webcast of the fireside chat will be available on the “Events” page of the Investors section of the COMPASS website. A replay of t
- Globe Newswire
COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology
Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK – 4 January 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, shared results today of a phase I study showing the feasibility of administering COMP360 psilocybin to up to six healthy participants simultaneousl
